Abstract
Parkinson’s disease (PD) etiology is associated with genetic and environmental factors that lead to a loss of dopaminergic neurons. However, the functional interpretation of PD-associated risk variants and how other midbrain cells contribute to this neurodegenerative process are poorly understood. Here, we profiled >41,000 single-nuclei transcriptomes of postmortem midbrain tissue from 6 idiopathic PD (IPD) patients and 5 matched controls. We show that PD-risk variants are associated with glia- and neuron-specific gene expression patterns. Furthermore, Microglia and astrocytes presented IPD-specific cell proliferation and dysregulation of genes related to unfolded protein response and cytokine signalling. IPD-microglia revealed a specific pro-inflammatory trajectory. Finally, we discovered a neuronal cell cluster exclusively present in IPD midbrains characterized by CADPS2 overexpression and a high proportion of cycling cells. We conclude that elevated CADPS2 expression is specific to dysfunctional dopaminergic neurons, which have lost their dopaminergic identity and unsuccessful attempt to re-enter the cell cycle.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
S.Sm. and S.P. received funding from the Luxembourg National Research Fund (FNR) within the PARK-QC DTU (PRIDE17/12244779/PARK-QC). A.G. is supported by the FNR within the framework of the ATTRACT (Model IPD, FNR9631103) career development program. C.M.M. is supported by grants to the Newcastle Brain Tissue Resource from UK MRC (MR/L016451/1), the Alzheimer's Society and Alzheimer's Research Trust through the Brains for Dementia Research Initiative, and from National Institutes for Health Research Biomedical Research Centre Newcastle. Moreover, A.G., P.M. and Z.L. obtained FNR funding as part of the National Centre of Excellence in Research on Parkinson's disease (NCER-PD, FNR11264123) grant, and A.G. and P.M. from the FNR Core MiRisk-PD (C17/BM/11676395) grant. M.S. is supported by grants from the Deutsche Forschungsgemeinschaft (DFG) (SP1532/3-1, SP1532/4-1 and SP1532/5-1), the Max Planck Foundation and the Deutsches Zentrum fur Luft-und Raumfahrt (DLR 01GM1925). The Parkinson's UK Brain Bank is funded by Parkinson's UK, a charity registered in England and Wales (258197) and in Scotland (SC037554).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients and controls gave written informed consent with the brain banks which, together with the ethics review panel of the University of Luxembourg, approved the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data for the 11 samples presented in this study are available in the Gene Expression Omnibus (GEO) with accession number GSE157783. Single-cell human embryonic midbrain dataset was available in the GSE76381 GEO accession.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE157783
